Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease

NCT02680756 is registered in ClinicalTrials.gov with Shield Therapeutics as lead sponsor.

NCT NCT02680756
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02680756 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Controlled, Multicentre Study With Oral Ferric Maltol (Feraccru) or Intravenous Iron (Ferric Carboxy Maltose; FCM), for the Treatment of Iron Deficiency Anaemia in Subjects With Inflammatory Bowel Disease
Lead sponsor
Shield Therapeutics
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2016
Completion date
January 31, 2019
Enrollment
250 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

anemia, iron-deficiency, crohn's disease, inflammatory bowel disease